These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 9644979)

  • 1. [Combined use of 5 alpha-reductase inhibitors and alpha-l adrenergic receptor blockers in patients with benign prostatic hyperplasia].
    Tkachuk VN; Al'-Shukri SKh; Luk'ianov AE; Kornienko VI; Kuz'min IV
    Urol Nefrol (Mosk); 1998; (3):5-8. PubMed ID: 9644979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The efficacy of alfuzosin (dalfaz) in patients with benign prostatic hyperplasia].
    Tkachuk VN; Kuz'min IV
    Urol Nefrol (Mosk); 1998; (2):38-40. PubMed ID: 9577703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5alpha-reductase inhibitors/finasteride.
    Stoner E
    Prostate Suppl; 1996; 6():82-7. PubMed ID: 8630236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of medical treatment in benign prostatic hyperplasia.
    Kim CI; Chang HS; Kim BK; Park CH
    Urology; 2006 Nov; 68(5):1015-9. PubMed ID: 17095071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ; Miner M
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia.
    Kuritzky L; Rosenberg MT; Sadovsky R
    Int J Clin Pract; 2006 Mar; 60(3):351-8. PubMed ID: 16494652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A trial of the use of finasteride and terazosin in patients with benign prostatic hyperplasia].
    Pushkar' DIu; Kosko DV; Loran OB; Kan IaD; Sapozhnikov IM; Tevlin KP
    Urol Nefrol (Mosk); 1995; (4):32-5. PubMed ID: 7571199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative evaluation of the effectiveness and safety of combined drug therapy of patients with benign prostatic hyperplasia with finasteride and alfuzozine].
    Loran OB; Pushkar' DIu; Rasner PI
    Urologiia; 2002; (1):19-22. PubMed ID: 11877966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The treatment of patients with benign prostatic hyperplasia with Proscar MSD (finasteride)].
    Stepanov VN; Teodorovich OV; Seregin AV; Kadyrov ZA
    Urol Nefrol (Mosk); 1995; (5):28-30. PubMed ID: 8571480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.
    Debruyne FM; Jardin A; Colloi D; Resel L; Witjes WP; Delauche-Cavallier MC; McCarthy C; Geffriaud-Ricouard C
    Eur Urol; 1998 Sep; 34(3):169-75. PubMed ID: 9732187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical treatment as an alternative to surgery in the management of benign prostatic hypertrophy.
    Bredin HC
    Ir Med J; 1996; 89(3):86, 88. PubMed ID: 8707527
    [No Abstract]   [Full Text] [Related]  

  • 13. Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.
    Elterman DS; Lawrentschuk N; Guns E; Hersey K; Adomat H; Wood CA; Fleshner N
    J Urol; 2010 May; 183(5):2085-9. PubMed ID: 20303529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy.
    Kuo HC; Liu HT
    Scand J Urol Nephrol; 2009; 43(3):206-11. PubMed ID: 19308807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor.
    Boudon C; Lobaccaro JM; Lumbroso S; Lechevallier E; Mottet N; Gibelin B; Sultan C
    Cell Mol Biol (Noisy-le-grand); 1995 Dec; 41(8):1007-15. PubMed ID: 8747081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate.
    Roehrborn CG
    Prostate Cancer Prostatic Dis; 2006; 9(2):121-5. PubMed ID: 16304557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [5-alpha reductase inhibitors or alpha blockers? The combination brakes best prostatic hyperplasia].
    MMW Fortschr Med; 2002 Oct; 144(44):56. PubMed ID: 12494605
    [No Abstract]   [Full Text] [Related]  

  • 18. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia.
    Agha AH; Roy JB; Culkin DJ; Lyon K
    Adv Ther; 1995; 12(6):361-6. PubMed ID: 10163332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term results of proscar (finasteride, MSD) treatment of patients with benign prostatic hyperplasia].
    Tkachuk VN; Al'-Shukri SKh; Kornienko VI; Kuz'min IV
    Urol Nefrol (Mosk); 1998; (4):37-9. PubMed ID: 9727320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.